You Can Have Your Cake and Eat it Too

November 16, 2023
You must provide your professional email address to view this content.

Anti-obesity drugs offer the potential to stem a major global health concern, which is something that sustainability investors should rightfully be excited about. Eli Lilly and Novo Nordisk both appear priced for near perfection; manufacturing challenges, low cooperation from insurers, and physical side effects are just some of the things that may go wrong and suggest investors should be patient. On the flip side, dire predictions about the upheaval to snack food companies and fast-food chains are exaggerated. These companies will adjust their product offerings and their prices to remain relevant to a more satiated consumer.

Disclaimer / Securities Disclosure

SECURITIES DISCLOSURE
The author(s) of this research note do (does) not personally hold a any position in any of the above-mentioned securities.
Nordis Capital (SMS’ sister company) does not hold any position in the above-mentioned securities in its ESG funds.

DISCLAIMER
© Sustainable Market Strategies, a division of SMS Financial Technologies inc. Redistribution prohibited without prior consent. This report has been prepared by Sustainable Market Strategies mainly for distribution to market professionals and institutional investors. It should not be considered as investment advice or a recommendation to purchase any particular security, strategy, or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.